Pyng Medical Corp. Announces Investor Relations Appointment
Vancouver, BC - Pyng Medical Corp. is pleased to announce the engagement of QIS Capital (547853 BC Ltd.) as the Company’s Investor Relations Consultant.
Pyng’s objective is to increase awareness of the Company in the investment community. QIS Capital will bear the responsibility to coordinate Pyng’s public and investor relations activities and to communicate specifically with the retail audience. QIS Capital will provide corporate information to its large following of investors and will also communicate the investment merits of the Company through its relationships with newsletter editors, brokers, media, and analysts.
As part of this agreement, Pyng Medical has been granted the opportunity to participate in The Small-cap Conference to be hosted in Vancouver on March 31, 2007.
QIS Capital (547853 BC Ltd.), an investor relations and small-cap investor research source, is a limited company located in Kamloops, BC. The company is owned and operated by Doren Quinton. Pyng Medical and 547853 BC Ltd. operate at arms length and are independent of one another.
This Investor Relations Agreement covers a period of six months from March - August 2007 at a cost of $2500 per month. 547853 BC Ltd. has also been granted a total of 40,000 options exercisable at $0.36 per share for a period of 2 years. These options will vest on a 25% basis every three months from the effective date of the agreement.
547853 BC Ltd. and its principal shareholders hold either directly or indirectly a total of 35,000 shares of Pyng Medical Corp. 547853 BC Ltd. and its shareholders may purchase shares in Pyng Medical from time to time for investment purposes.
About Pyng Medical Corp.
Pyng Medical Corp. is a world-leader in intraosseous infusion with its proprietary award-winning FAST1™ Intraosseous Infusion System. The FAST1™ is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
For More Information
David Christie
Pyng Medical Corp.
(604) 303-7964
www.pyng.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.